Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2869-2872

  Koletar, Susan L ^a,h   Berry, Alison J ^b   Cynamon, Michael H ^c   Jacobson, Jeffrey ^d   Currier, Judith S ^e   MacGregor, Rob Roy ^f   Dunne, Michael W ^g   Williams, Debra J ^g  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h N 1135 Doan Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTERIAL COUNT; BLOOD CULTURE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032762172     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2869     Document Type: Article

References (22)

1. Bermudez, L. E., M. Petrofsky, P. Kolonoski, and L. S. Young. 1998. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob. Agents Chemother. 42:180-183.
2. Centers for Disease Control and Prevention. 1997. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morbid. Mortal. Weekly Rep. 46:12-13.
3. Chaisson, R. E., C. A. Benson, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, J. C. Craft, and F. R. Sattler. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind dose-ranging study in patients with AIDS. Ann. Intern. Med. 121: 905-911.
4. Chaisson, R. E., P. Keiser, M. Pierce, W. J. Fessel, J. Ruskin, C. Lahart, C. A. Benson, K. Meek, N. Siepman, and J. C. Craft. 1997. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 11:311-317.
5. Chin, D. P., A. L. Reingold, E. N. Stone, E. Vittinghoff, C. R. Horsburgh, Jr., E. M. Simon, D. M. Yajko, W. K. Hadley, S. M. Ostroff, and P. C. Hopewell. 1994. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J. Infect. Dis. 170:578-584.
6. Dautzenberg, B., T. Saint Marc, M. C. Meyohas, M. Eliaszewitch, F. Haniez, A. M. Rogues, S. De Wit, L. Cotte, J. P. Chauvin, and J. Grosset. 1993. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch. Intern. Med. 153:368-372.
7. Dautzenberg, B., C. Truffot, S. Legris, M. C. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, and J. Grossel. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am. Rev. Respir. Dis. 144:564-569.
8. Dube, M. P., F. R. Sattler, F. J. Torriani, D. See, D. V. Havlir, C. A. Kemper, M. G. Dezfuli, S. A. Bozzette, A. E. Bartok, J. M. Leedom, J. G. Tilles, and J. A. McCutchan. 1997. A randomized evaluation of ethambutol for prevention of relapse and drug resistance of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy, J. Infect. Dis. 176: 1225-1232.
9. Fernandes, P. B., D. J. Hardy, D. McDaniel, C. W. Hanson, and R. N. Swanson. 1989. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother. 33:1531-1534.
10. Girard, A. E., D. Girard, A. R. English, T. D. Gootz, C. R. Cimochowski, J. A. Faiella, S. L. Haskell, and J. A. Retsema. 1987. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 31:1948-1954.
11. Havlir, D. V., M. P. Dube, F. R. Sattler, D. N. Forthal, C. A. Kemper, M. W. Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, Jr., M. D. Witt, S. A. Bozzette, and J. A. McCutchan. 1996. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N. Engl. J. Med. 335:392-398.
12. Heifets, L., N. Mor, and J. Vanderkolk. 1993. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents Chemother. 37:2364-2370.
13. Inderlied, C. B., P. T. Kolonoski, M. Wu, and L. S. Young. 1989. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J. Infect. Dis. 159:994-997.
14. Inderlied, C. B., L. S. Young, and J. K. Yamada. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob. Agents Chemother. 31:1697-1702.
15. Lounis, N., J. Baohong, C. Truffot-Pernot, and J. Grosset. 1995. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob. Agents Chemother. 39: 608-612.
16. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg, 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
17. Phillips, P., C. Zala, D. Rouleau, and J. S. G. Montaner. 1997. Mycobacterial lymphadenitis: can highly active antiretroviral therapy (HAART) unmask subclinical infection? In Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C. [Poster 620.]
18. Pierce, M., S. Crampton, D. Henry, L. Heifets, A. LaMarca, M. Montecalvo, G. P. Wormser, H. Jablonowski, J. Jemsek, M. Cynamon, B. G. Yangco, G. Notario, and J. C. Craft. 1996. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335:384-391.
19. Race, E. M., J. Adelson-Mitty, G. R. Kriegel, T. F. Barlam, K. A. Reimann, N. L. Letvin, and A. J. Japour. 1998. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor in patients with advanced HIV-1 disease. Lancet 351:252-255.
20. Shafran, S. D., J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachilis, R. G. Lalonde, M. M. Fanning, and C. M. Tsoukas. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N. Engl. J. Med. 335:377-383.
21. Ward, T. T., D. Rimland, C. Kauffman, M. Huycke, T. G. Evans, and L. Heifets. 1998. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 27:1278-1285.
22. Young, L. S., L. Wiviott, M. Wu, P. Kolonoski, R. Bolan, and C. B. Inderlied. 1991. Azithromycin as treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 338:1107-1109.